Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394433 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00394433 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 38 participants.
The verdict
NCT00394433, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the combination of docetaxel, cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric cancer and how the cancer responds to this combination. Bevacizumab is a new drug that is believed to stop the formation of new blood vessels that carry nutrients to tumors. Bevacizumab is approved for use in metastatic colon and rectal cancer. Docetaxel, cisplatin and irinotecan are traditional chemotherapy agents that have been tested together in another clinical trial for esophageal and gastric cancer. It is hoped that adding bevacizumab to this regimen will make the treatment more effective.
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394433
The ClinicalTrials.gov registry entry for NCT00394433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00394433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394433 about?
NCT00394433 is a clinical study titled "Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer". The purpose of this research study is to determine if the combination of docetaxel, cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric cancer and how the cancer responds to this combination. Bevacizumab is a new drug that is believed to stop the formation of new ...
What is the current status of trial NCT00394433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2006-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00394433?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00394433?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.